701977-09-5

Basic information

• Product Name: N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide( MK 0364)
• Synonyms: N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide( MK 0364);MK 0364;N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide;Taranabant;Tranabant;N-(3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;Propanamide, N-((1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)-2-pyridinyl)oxy)-;Taranabant [usan]
• CAS NO: 701977-09-5
• Molecular Formula: C₂₇H₂₅ClF₃N₃O₂
• Molecular Weight: 515.95
• Mol File: 701977-09-5.mol
• Article Data: 10

Chemical Properties

• Melting Point: 106.0-106.3 °C
• Boiling Point: 634.2 °C at 760 mmHg
• Flash Point: 337.4 °C
• Appearance: /
• Density: 1.30
• PKA: 14.55±0.46(Predicted)
• CAS DataBase Reference: N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide( MK 0364)(CAS DataBase Reference)
• NIST Chemistry Reference: N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide( MK 0364)(701977-09-5)
• EPA Substance Registry System: N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide( MK 0364)(701977-09-5)

Safety Data

• Hazardous Substances Data: 701977-09-5(Hazardous Substances Data)

Usage

Description

N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide (MK 0364) is a chemical compound with the molecular formula C28H24ClF3N4O2. It is a potent and selective potassium channel opener, known for its potential therapeutic applications in treating neurological conditions such as epilepsy, neuropathic pain, anxiety, and depression. MK 0364 modulates the activity of specific potassium channels in the brain and nervous system, which can help reduce abnormal electrical activity and alleviate symptoms associated with these conditions. Its complex chemical structure and unique mode of action make it a promising candidate for further research and development in the field of neuroscience and drug discovery.

Uses

Used in Pharmaceutical Industry:
MK 0364 is used as a therapeutic agent for the treatment of neurological conditions such as epilepsy and neuropathic pain. Its application is based on its ability to modulate the activity of specific potassium channels in the brain and nervous system, which can help reduce abnormal electrical activity and alleviate symptoms associated with these conditions.
Used in Research and Development:
MK 0364 is used as a research compound for further investigation of its potential applications in treating anxiety and depression. Its unique mode of action and complex chemical structure make it a valuable candidate for exploring new therapeutic approaches in the field of neuroscience and drug discovery.
Used in Drug Discovery:
MK 0364 is employed as a lead compound in the development of new drugs targeting potassium channels for the treatment of various neurological conditions. Its potent and selective activity, along with its potential to alleviate symptoms associated with epilepsy, neuropathic pain, anxiety, and depression, make it a promising candidate for further optimization and development into effective therapeutic agents.

InChI:InChI=1/C27H25ClF3N3O2/c1-17(34-25(35)26(2,3)36-24-12-9-21(16-33-24)27(29,30)31)23(14-18-7-10-22(28)11-8-18)20-6-4-5-19(13-20)15-32/h4-13,16-17,23H,14H2,1-3H3,(H,34,35)

Upstream product

• 876365-72-9 3-{(1S,2S)-1-(4-chlorobenzyl)-2-[(2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanoyl)amino]propyl}benzamide 
• 605680-62-4 2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanoic acid 
• 104-83-6 1-Chloro-4-(chloromethyl)benzene 
• 941280-52-0 (2R,3S)-3-(3-bromophenyl)-4-(4-chlorophenyl)butan-2-ol 
• 1002752-54-6 (3S)-3-(3-bromophenyl)-4-(4-chlorophenyl)butan-2-one 
• 941280-51-9 2-(3-bromophenyl)-3-(4-chlorophenyl)propionic acid 
• 1204241-05-3 C₁₅H₁₁BrCl₂O 
• 1878-67-7 3-Bromophenylacetic acid 
• 876365-70-7 N-[(1Z)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylprop-1-en-1-yl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide 
• 732982-66-0 N-(1S,2S)-[2-(3-cyanophenyl)-3-(4-chlorophenyl)-1-methylpropyl]amine 
• 150529-73-0 methyl 2-(3-bromophenyl)acetatee 
• 622-95-7 4-chlorobenzyl bromide 
• 33252-63-0 2-hydroxy-5-(trifluoromethyl)pyridine 

Relevant articles and documents

New efficient asymmetric synthesis of taranabant, a CB1R inverse agonist for the treatment of obesity

Taranabant (1) is a cannabinoid-1 receptor (CB1R) inverse agonist that was recently in late-stage clinical development for the treatment of obesity. The previously employed synthesis exhibited a number of shortcomings for continuing development, and in th

Catalytic, enantioselective synthesis of taranabant, a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity

Chiral amide 1 (MK-0364, taranabant) is a potent, selective, and orally bioavailable cannabinoid-1 receptor (CB-1R) inverse agonist indicated for the treatment of obesity. An asymmetric synthesis featuring a dynamic kinetic resolution via hydrogenation fo

Cyanation of aromatic halides

A practical, ligand-free cyanation of aryl bromides employs Pd catalyst in combination with a non-toxic cyanide source, Mn[Fe(CN)6] (M=K or Na; n is 3 or 4), or a hydrate thereof, and a base. The reactions are performed in a polar aprotic solvents and provide the corresponding aryl nitrile in 83-96% yield, typically in less than 5 h.